Aortic Valve Market

Overview

The global Aortic Valve Market was valued at USD 14.6 billion in 2025 and is projected to reach USD 38.9 billion by 2034, growing at a CAGR of 11.5% during the forecast period (2026-2034). The market is shifting toward minimally invasive transcatheter procedures across a broader range of patient-risk groups, alongside new valves for aortic regurgitation, biomimetic designs, and redo-TAVR systems, reflecting a move toward lifetime valve management. Government initiatives such as the U.S. FDA's continued expansion of TAVR risk-category labeling and Breakthrough Device Designation pathway, the European Union's Medical Device Regulation (MDR) compliance framework for structural heart implants, China's National Medical Products Administration approval pathway for domestically developed transcatheter valves, and India's Production Linked Incentive (PLI) scheme for medical device manufacturing are collectively easing regulatory timelines and encouraging domestic production capacity for aortic valve technologies in several major markets. By region, North America held the largest share of the Aortic Valve Market in 2025, supported by high TAVR procedural volumes, favorable CMS reimbursement, and a concentrated base of leading device manufacturers. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rising aortic stenosis prevalence in China and India, expanding NMPA-approved domestic transcatheter platforms, and improving access to structural heart programs across the region.

Market Size & Share

Market Dynamics

KEY MARKET TREND

AI-Enabled Diagnostics and Structural Heart Imaging Emerging as a Transformational Trend

• Hospitals are increasingly deploying AI-assisted echocardiography and CT-based annular sizing software to plan TAVR procedures, shortening pre-procedural workup time and improving valve-sizing accuracy for structural heart teams.
• Structural heart programs are combining patient-specific 3D-printed anatomical models with fusion imaging to rehearse complex transcatheter valve deployments, reducing paravalvular leak and improving coronary-access planning in anatomically challenging cases.
• Device manufacturers are integrating digital procedure-planning platforms directly with valve delivery systems, enabling physicians to simulate valve-in-valve and redo-TAVR scenarios ahead of intervention as more patients require re-intervention on a previously implanted valve.
• Edwards Lifesciences is sponsoring the American Heart Association's Heart Valve Initiative, a multi-year program focused on early diagnosis, clinician training, hospital certification, and public awareness intended to improve care for the 28 million people worldwide living with heart valve disease.

KEY MARKET DRIVER

Rising Prevalence of Aortic Stenosis Among an Aging Global Population Is the Key Driver

• The World Health Organization projects that the global population aged 65 and older will more than double from 761 million in 2021 to approximately 1.6 billion by 2050, directly expanding the pool of patients at risk of degenerative aortic valve disease.
• Regulators have progressively broadened TAVR eligibility criteria over the past decade, moving from extreme- and high-risk indications to intermediate-, low-risk, and now asymptomatic patient populations, substantially widening the addressable patient base for transcatheter therapy.
• Long-term data from pivotal randomized trials, including PARTNER 3 and the Evolut Low Risk Trial, continue to support extending TAVR to younger, lower-surgical-risk patients, reinforcing physician and payer confidence in transcatheter treatment durability.
• The European Union’s Safe Hearts Plan strengthens cardiovascular disease prevention, early detection, screening, and treatment across member states, supporting earlier diagnosis and management of cardiovascular conditions among aging populations and indirectly increasing demand for advanced interventions for conditions such as aortic stenosis.

KEY MARKET OPPORTUNITY:

Expansion Into Aortic Regurgitation and Emerging-Market Patient Populations Creates Significant Opportunity

• Patients with severe native aortic regurgitation, historically unaddressed by dedicated transcatheter devices, gained an approved treatment option following the FDA's March 2026 approval of JenaValve's Trilogy transcatheter heart valve system based on the ALIGN-AR pivotal trial.
• Manufacturers are directing capital toward next-generation biomimetic and polymer-leaflet valve platforms intended to improve durability for younger patients; Medtronic agreed in January 2026 to purchase up to USD 90 million in shares of Anteris Technologies Global Corp to support the DurAVR biomimetic transcatheter valve program.
• Aortic stenosis prevalence in China is projected to rise from more than 5 million patients currently to over 7 million by 2030, and continued NMPA approvals for domestically developed transcatheter platforms are expanding access to minimally invasive treatment across the region.
• Meril Life Sciences' LANDMARK randomized controlled trial, with one-year outcomes presented at PCR London Valves 2025, provided the first head-to-head comparison of an India-developed transcatheter valve against the two dominant Western platforms, reinforcing the clinical evidence base needed for broader international adoption of emerging-market valve technologies.

Aortic Valve Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Transcatheter Aortic Valve Replacement (TAVR) held the largest market share in 2025 and is also projected to grow at the fastest CAGR during the forecast period, having surpassed conventional surgical aortic valve replacement in overall revenue as regulatory approvals expanded across all surgical-risk categories. TAVR's minimally invasive transfemoral approach, shorter hospital stays, and strong outcomes data from PARTNER and Evolut trial programs have made it the preferred option for the majority of eligible patients, supported by favorable reimbursement in the United States, Europe, and increasingly in Asia-Pacific markets. Rising adoption of alternative access routes and same-day discharge protocols is further accelerating procedural volumes across developed and emerging markets alike.

Product Type categories include

• Transcatheter Aortic Valve Replacement (TAVR) (Largest & Fastest-Growing Segment)
• Conventional Surgical Aortic Valve Replacement (SAVR)
• Rapid-Deployment Aortic Valves
• Balloon Aortic Valvuloplasty
• Others

Analysis by Valve Type

Tissue valves held the largest market share in 2025, supported by their avoidance of lifelong anticoagulation therapy and strong suitability for both surgical and transcatheter delivery platforms. Bovine and porcine pericardial tissue valves dominate current commercial portfolios across nearly all major manufacturers, including the SAPIEN, Evolut, and Myval platforms, due to favorable hemodynamic performance and broad clinical familiarity among structural heart teams.

Polymeric valves are projected to grow at the fastest CAGR during the forecast period, supported by emerging biomimetic single-tissue and polymer-leaflet designs intended to improve long-term durability for younger patients who would otherwise require multiple re-interventions over their lifetime. Continued clinical investment in this category, including Anteris Technologies' DurAVR platform and Foldax's polymer valve programs, is expected to support accelerating adoption as pivotal trial data matures.

Valve Type categories include

• Tissue Valves (Largest Segment)
• Mechanical Valves
• Synthetic Valves (Highest CAGR Segment)
• Allograft Valves
• Others

Analysis by Access Route

Transfemoral access held the largest market share in 2025, accounting for the substantial majority of TAVR procedures performed globally, as it avoids the need for surgical incisions required by transapical or transaortic approaches and enables faster patient recovery. Widespread physician training, dedicated delivery-catheter design improvements, and favorable outcomes data have reinforced transfemoral access as the default approach across nearly all patient anatomies suitable for TAVR.

Transcarotid are projected to grow at the fastest CAGR during the forecast period, offering an alternative for patients with unfavorable femoral or iliac anatomy who would otherwise require more invasive transapical or transaortic surgery. Growing operator experience and dedicated delivery systems designed for these alternative access routes are expanding the pool of patients eligible for a minimally invasive transcatheter procedure.

Access Route categories include

• Transfemoral (Largest Segment)
• Transapical
• Transaortic
• Subclavian (Highest CAGR Segment)
• Others

Analysis by End User

Hospitals held the largest market share in 2025, reflecting the continued need for on-site cardiac surgery backup, catheterization laboratory infrastructure, and multidisciplinary heart-team support required for aortic valve procedures, particularly for higher-risk patients and complex anatomies requiring surgical conversion capability. The availability of intensive care, post-procedure monitoring, and comprehensive cardiovascular services also strengthens hospitals’ role in managing complex aortic valve cases.

Ambulatory surgical centers are projected to grow at the fastest CAGR during the forecast period, supported by the adoption of same-day discharge and next-day discharge protocols for low-risk transfemoral TAVR patients, which reduce procedural costs while maintaining comparable safety outcomes to traditional inpatient pathways. Growing demand for cost-efficient cardiovascular care and shorter hospital stays is further supporting the expansion of ambulatory TAVR programs.

End-User categories include

• Hospitals (Largest Segment)
• Ambulatory Surgical Centers (Highest CAGR Segment)
• Specialty Cardiac Clinics
• Others

By Region

Aortic Valve Market Share 2025, (by Region)

North America

46%

South America

xx%

Europe

24%

Middle East Africa

xx%

Asia Pacific

xx%

North America held the largest market share in 2025, accounting for 46% of global market share, supported by high TAVR procedural volumes, established Centers for Medicare & Medicaid Services reimbursement pathways, advanced structural heart programs, and the concentrated presence of leading manufacturers including Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific. The United States (Largest Country Market) leads the region through its large base of structural heart programs, high procedural volumes, and continued expansion of TAVR indications, including the United States Food and Drug Administration's 2025 approval of expanded indications for Edwards' SAPIEN transcatheter heart valve systems in patients with asymptomatic severe aortic stenosis. Canada is witnessing steady growth in transcatheter valve adoption, supported by expanding cardiac care infrastructure and investment in catheterization capabilities, while Mexico is experiencing gradual adoption as specialist cardiovascular centers and access to minimally invasive valve therapies expand.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by rising aortic stenosis prevalence, expanding domestic transcatheter valve manufacturing, improving structural heart infrastructure, and broader access to minimally invasive treatment across major markets. China (Largest Country Market) leads the region, supported by the expansion of domestic transcatheter heart valve technologies and growing adoption of TAVR, while India (Fastest-Growing Country Market) is benefiting from increasing structural heart capacity, specialist training, and the expanding use of domestically developed technologies such as Meril Life Sciences' Myval transcatheter heart valve, which has generated clinical evidence and international adoption. Japan continues to benefit from an established cardiovascular intervention ecosystem and an aging population, while South Korea is supported by advanced cardiac centers and increasing adoption of transcatheter therapies. Rest of Asia-Pacific is expected to gain gradually as healthcare infrastructure, specialist capabilities, and access to advanced valve technologies improve.

Countries and Regions Covered

North America (Largest Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• Germany (Largest Country Market)
• United Kingdom
• France
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The market is consolidated, with Edwards Lifesciences holding more than 55% share of the global TAVR market in 2025 and the top five participants, Edwards Lifesciences, Abbott Laboratories, Boston Scientific, Medtronic, and Meril Life Sciences, together accounting for roughly 80% of the transcatheter segment. The competitive landscape includes Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, JenaValve Technology, Inc., Meril Life Sciences Pvt. Ltd., Artivion, Inc., Biotronik SE & Co. KG, Colibri Heart Valve LLC, Anteris Technologies Global Corp., Venus Medtech (Hangzhou) Inc., Peijia Medical Ltd., Foldax, Inc., TTK Healthcare Limited, and Braile Biomedica. High capital requirements, lengthy pivotal-trial timelines, and stringent regulatory oversight continue to reinforce concentration among a small number of global players, as illustrated by Boston Scientific's May 2025 decision to discontinue its ACURATE neo2 and ACURATE Prime platforms worldwide after the devices failed to demonstrate non-inferiority against SAPIEN 3 and Evolut in a pivotal randomized trial. Leading companies are prioritizing indication expansion, redo-TAVR capability, and strategic investment in differentiated next-generation valve technologies, including Medtronic's equity investment in Anteris Technologies, to defend competitive positioning, while regional manufacturers in India, China, and Brazil continue to strengthen their presence in cost-sensitive and underserved markets.

Key Players

• Edwards Lifesciences Corporation (United States)
• Medtronic plc (Ireland)
• Abbott Laboratories (United States)
• Boston Scientific Corporation (United States)
• JenaValve Technology, Inc. (United States)
• Meril Life Sciences Pvt. Ltd. (India)
• Artivion, Inc. (United States)
• Biotronik SE & Co. KG (Germany)
• Colibri Heart Valve LLC (United States)
• Anteris Technologies Global Corp. (Australia)
• Venus Medtech (Hangzhou) Inc. (China)
• Peijia Medical Ltd. (China)
• Foldax, Inc. (United States)
• TTK Healthcare Limited (India)
• Braile Biomedica (Brazil)

Recent Market Developments

• January 2025: Abbott launched Navitor Vision in India, an upgraded TAVI/TAVR system with three radiopaque markers designed to improve valve visualization and positioning during implantation.
• May 2025: Boston Scientific announced the voluntary global discontinuation of its ACURATE neo2 and ACURATE Prime TAVR systems after the devices failed to demonstrate non-inferiority against SAPIEN 3 and Evolut in the pivotal ACURATE IDE randomized trial, reducing near-term platform competition in the self-expanding TAVR segment.
• August 2025: Medtronic received FDA approval for an expanded Redo-TAVR indication for its Evolut transcatheter aortic valve systems, allowing implantation of a new Evolut valve inside any previously failed transcatheter valve regardless of the original manufacturer, addressing a growing population of patients with degenerating first-generation transcatheter valves.
• March 2026: JenaValve Technology received FDA premarket approval for its Trilogy transcatheter heart valve system for the treatment of symptomatic, severe native aortic regurgitation in patients at high or greater surgical risk, based on the ALIGN-AR pivotal trial, becoming the first and only transcatheter device approved in the United States for this previously unaddressed patient population.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is an Aortic Valve?

2

What is the CAGR of the Aortic Valve Market?

3

Which product type leads the Aortic Valve Market?

4

Which end user dominates the Aortic Valve Market?

5

Which valve type has the highest market share?

6

What are the latest trends in the Aortic Valve Market?

7

Who are the key players in the Aortic Valve Market?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates